Under-stage and Overlook of Peritoneal Spread from Bladder Urothelial Carcinoma

Liaw, Chuang-Chi; Chuang, Cheng-Keng; Chang, Ying-Hsu; Chang, John Wen‐Cheng; Liao, Tzu-Yao; Juan, Yu-Hsiang

doi:10.21873/invivo.11327

Cited by 2 publications

(3 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Peritoneal involvement due to MUC is commonly seen. While such lesions are often overlooked, under-staged, and difficult to confirm (18,19), they responded to chemotherapy in our previous report (2).…”

Section: Instances Without An Unfavorable Metastatic Conditionmentioning

confidence: 83%

Survival Benefit for Patients With Metastatic Urothelial Carcinoma Receiving Continuous Maintenance Chemotherapy

Liaw

Liao

Tsui

et al. 2019

In Vivo

Self Cite

View full text Add to dashboard Cite

Background/Aim: Urothelial carcinoma is a chemo-sensitive cancer. We investigated the contributory factors to survival benefit of metastatic urothelial carcinoma (MUC) patients receiving continuous maintenance chemotherapy. Patients and Methods: Inclusion criteria were: i) pathology-confirmed urothelial carcinoma, ii) metastatic lesions identified mainly on pre-therapy computed tomography (CT) scans, and iii) inpatient-administered chemotherapy of at least three cycles. Chemotherapy regimens included 5-fluorouracil, leucovorin, cisplatin, and gemcitabine. Results: A total of 139 cases were enrolled in this study. The overall objective response rate was 60% and the median survival time was 17 months. Eight-two (59%) patients had inflammation-related symptoms following the course of chemotherapy. Fifty-five (41%) patients survived more than two years. All patients exhibited various fibrosis formations. No patient experienced unfavorable metastatic conditions. Inflammation-related symptoms remained in 28 (51%) patients. We found that surgery, invasive procedures, and infection likely led to a rapid tumor progression. Conclusion: Continuous maintenance chemotherapy targeting chemo-sensitive tumors, administered at metronomic intervals and focus on tumor microenvironment, can increase MUC survival benefits.

show abstract

Section: Instances Without An Unfavorable Metastatic Conditionmentioning

confidence: 83%

Survival Benefit for Patients With Metastatic Urothelial Carcinoma Receiving Continuous Maintenance Chemotherapy

Liaw

Liao

Tsui

et al. 2019

In Vivo

Self Cite

View full text Add to dashboard Cite

show abstract

“…Liaw et al . hypothesized that the subperitoneal bladder cancer spreads via the peritoneal lining 8 . Sawant et al .…”

Section: Figurementioning

confidence: 99%

“…1 Liaw et al hypothesized that the subperitoneal bladder cancer spreads via the peritoneal lining. 8 Sawant et al classified the following ways of bladder cancer spread: iatrogenic, haematogenic or lymphogenic way. 7 The first treatment option for a locoregional disease is tumour excision and partial cystectomy with or without pelvic lymph node dissection followed by cisplatin-based chemotherapy.…”

mentioning

confidence: 99%

Cyclops' eye‐like large ulcerated umbilical mass: a rare presentation of urachal cancer

Larentzakis

Eleftheriou

Zografos

et al. 2020

ANZ Journal of Surgery

View full text Add to dashboard Cite

Under-stage and Overlook of Peritoneal Spread from Bladder Urothelial Carcinoma

Abstract: Initial pre-therapeutic staging is easily overlooked regarding peritoneal spread from bladder urothelial carcinoma. Combined axial and coronal views of CT scans can help identify peritoneal involvement.

Cited by 2 publications

References 18 publications

Survival Benefit for Patients With Metastatic Urothelial Carcinoma Receiving Continuous Maintenance Chemotherapy

Survival Benefit for Patients With Metastatic Urothelial Carcinoma Receiving Continuous Maintenance Chemotherapy

Cyclops' eye‐like large ulcerated umbilical mass: a rare presentation of urachal cancer

Contact Info

Product

Resources

About